Targeted Oncology

, Volume 12, Issue 6, pp 841–842 | Cite as

Author’s Reply to Arnaud Uguen: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”

Letter to the Editor
  • 47 Downloads

Notes

Compliance with Ethical Standards

Funding

The study was supported by academic grants from Lilly, Astra Zeneca, and Boehringer Ingelheim. The sponsors played no role in the design or performance of the study, data analysis, or manuscript preparation. The results belong to Groupe Français d’Oncologie Thoracique (GFPC). The data were analyzed by the GFPC statistician and interpreted by the authors.

Conflict of Interest

Jean-Bernard Auliac has received honoraria for attending scientific meetings, speaking, organizing research, or consulting from AstraZeneca, Boehringer Ingelheim, Hoffman-Roche, Lilly, MSD, BMS, and Pfizer. Christos Chouaid has received honoraria for attending scientific meetings, speaking, organizing research, or consulting from AstraZeneca, Boehringer Ingelheim, Hoffman-Roche, Lilly, Novartis, Amgen, MSD, BMS, and GlaxoSmithKline.

References

  1. 1.
    Uguen A .Comment on: “Non-Small-Cell Lung Cancer (NSCLC) harboring ALK translocations: clinical characteristics and management in a real-life setting: a French retrospective analysis (GFPC 02–14 study)”. Target Oncol. 2017;  https://doi.org/10.1007/s11523-017-0533-2.
  2. 2.
    Auliac JB, Monnet I, Dubos-Arvis C, et al. Non–Small-cell lung cancer (NSCLC) harboring ALK translocations: clinical characteristics and management in a real-life setting: a French retrospective analysis (GFPC 02-14 Study). Target Oncol. 2017;  https://doi.org/10.1007/s11523-017-0520-7.
  3. 3.
    Lantuejoul S, Rouquette I, Blons H, et al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46:207–18.CrossRefPubMedGoogle Scholar
  4. 4.
    Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11:487–95.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Service de Pneumologie et Oncologie ThoraciqueHôpital François- QuesnayMantes-la-JolieFrance
  2. 2.Service de PneumologieCHI CréteilCréteilFrance

Personalised recommendations